Shares of Radius Health Inc. (NASDAQ:RDUS) dropped 3.9% during trading on Wednesday . The stock traded as low as $40.31 and last traded at $40.75, with a volume of 246,197 shares changing hands. The stock had previously closed at $42.41.

RDUS has been the topic of several analyst reports. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a research report on Monday, April 4th. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Monday, May 9th. Goldman Sachs Group Inc. initiated coverage on shares of Radius Health in a research report on Wednesday, March 30th. They set a “neutral” rating and a $37.00 price target on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $70.00 price target on shares of Radius Health in a research report on Thursday, March 31st. Finally, Cowen and Company initiated coverage on shares of Radius Health in a research report on Friday, May 6th. They set an “outperform” rating on the stock. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Radius Health presently has an average rating of “Buy” and an average target price of $70.07.

The company has a 50-day moving average of $37.19 and a 200-day moving average of $36.03. The firm’s market capitalization is $1.69 billion.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.20. During the same quarter last year, the business posted ($0.47) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year. Analysts forecast that Radius Health Inc. will post ($3.71) EPS for the current year.

Other hedge funds have added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new stake in Radius Health during the fourth quarter valued at approximately $1,362,000. Wells Fargo & Company MN raised its stake in Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock valued at $25,984,000 after buying an additional 29,601 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock valued at $2,245,000 after buying an additional 5,683 shares in the last quarter. EAM Investors LLC acquired a new stake in Radius Health during the fourth quarter valued at approximately $2,816,000. Finally, New York State Common Retirement Fund raised its stake in Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock valued at $4,249,000 after buying an additional 18,259 shares in the last quarter.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.